CoChat

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model

Wang, Lei, Amoozgar, Zohreh, Huang, Jing, Saleh, Mohammad H., Xing, Deyin, Orsulic, Sandra, Goldberg, Michael S. · 2015 · Cancer Immunology Research

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

The lack of second-line treatment for relapsed ovarian cancer necessitates the development of improved combination therapies. Targeted therapy and immunotherapy each confer clinical benefit, albeit limited as monotherapies. Ovarian cancer is not particularly responsive to immune checkpoint blockade, so combination with a complementary therapy may be beneficial. Recent studies have revealed that a DNA methyl transferase inhibitor, azacytidine, alters expression of immunoregulatory genes in ovarian cancer. In this study, the antitumor effects of a related DNA methyl transferase inhibitor, decitabine (DAC), were demonstrated in a syngeneic murine ovarian cancer model. Low-dose DAC treatment increases the expression of chemokines that recruit NK cells and CD8(+) T cells, promotes their production of IFNγ and TNFα, and extends the survival of mice bearing subcutaneous or orthotopic tumors. While neither DAC nor immune checkpoint blockade confers durable responses as a monotherapy in this model, the efficacy of anti-CTLA-4 was potentiated by combination with DAC. This combination promotes differentiation of naïve T cells into effector T cells and prolongs cytotoxic lymphocyte responses as well as mouse survival. These results suggest that this combination therapy may be worthy of further consideration for improved treatment of drug-resistant ovarian cancer.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-15-0073

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 179

Metadata

Authors
Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • Johns Hopkins University (US)
  • 3Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Venue
Cancer Immunology Research
Published
2015-09-01
Volume
3
Issue
9
Pages
1030-1041
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2136708520
Cited by
173
References
50
Citations by year
2026: 5 · 2025: 19 · 2024: 10 · 2023: 16 · 2022: 20 · 2021: 23 · 2020: 15 · 2019: 17 · 2018: 14 · 2017: 20 · 2016: 12 · 2015: 2
FWCI
6.99
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Peking University
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
decitabine, hypomethylating agents, ovarian cancer, CTLA-4 blockade, immune checkpoint blockade, combination therapy, lymphocyte migration, natural killer cells, CD8+ T cells, chemokines, interferon-gamma, TNF-α, T cell differentiation, cytotoxic lymphocytes, drug-resistant cancer, syngeneic murine model
MeSH terms
Decitabine, Animals, Antineoplastic Agents, Ascitic Fluid, Azacitidine, Cell Movement, Cell Transformation, Neoplastic, Female, Humans, Immunotherapy, Killer Cells, Natural, Lymph Nodes, Ovarian Neoplasms, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Cytokines, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Xenograft Model Antitumor Assays, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0073
The paper
Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S. (2015). Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.